EGFR and adenocarcinoma: In Asian SqCC patients, incidence of EGFR mutation varies from 2% to 13%.8, 9 According to the updated CAP/IASLC/AMP Molecular Testing guideline, EGFR testing is recommended for adenocarcinomas and mixed lung cancers with an adenocarcinoma component in the setting of lung cancer resection specimens.